Thursday, 15 October 2026European Markets

VAN DE VELDE, CATANA GROUP, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - van de velde (van.br) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
van de velde (van.br) €33.00 6.95% 22.23%
catana group (catg.pa) €6.75 2.1% 29.84%
renault (rno.pa) €35.36 0.7% 5.64%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. van de velde (van.br)

6.95% forward dividend yield and 22.23% return on equity

van de velde nv, together with its subsidiaries, designs, develops, manufactures, and markets fashionable luxury lingerie and swimwear for women worldwide. it operates through two segments, business to business (b2b) and direct to consumer (d2c). the company offers its products under the primadonna, marie jo, andres sarda, and lingerie styling brands. it also operates retail websites; stores; and boutiques and department stores. the company was founded in 1919 and is headquartered in schellebelle, belgium. van de velde nv is a subsidiary of van de velde holding nv.

earnings per share

as for profitability, van de velde has a trailing twelve months eps of €2.81.

pe ratio

van de velde has a trailing twelve months price to earnings ratio of 11.74. meaning, the purchaser of the share is investing €11.74 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.23%.

volatility

van de velde's last week, last month's, and last quarter's current intraday variation average was a negative 0.62%, a negative 0.24%, and a positive 1.14%.

van de velde's highest amplitude of average volatility was 0.99% (last week), 1.04% (last month), and 1.14% (last quarter).

sales growth

van de velde's sales growth for the current quarter is 7.7%.

more news about van de velde.

2. catana group (catg.pa)

2.1% forward dividend yield and 29.84% return on equity

sa catana group manufactures and sells pleasure boats, sails, and motors in france and internationally. it also offers boat work, garage rentals, guarding, and berth services. the company markets its products under the catana, bali, and catspace brands. sa catana group was founded in 2001 and is headquartered in canet-en-roussillon, france.

earnings per share

as for profitability, catana group has a trailing twelve months eps of €0.57.

pe ratio

catana group has a trailing twelve months price to earnings ratio of 11.84. meaning, the purchaser of the share is investing €11.84 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.84%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, catana group's stock is considered to be overbought (>=80).

yearly top and bottom value

catana group's stock is valued at €6.75 at 22:30 est, way below its 52-week high of €7.72 and way higher than its 52-week low of €4.61.

volume

today's last reported volume for catana group is 35544 which is 32.59% below its average volume of 52734.

more news about catana group.

3. renault (rno.pa)

0.7% forward dividend yield and 5.64% return on equity

renault sa engages in the design, manufacture, sale, repair, maintenance, and leasing of motor vehicles in europe, eurasia, africa, the middle east, the asia pacific, and the americas. it also engages in the design and production of parts and equipment used for manufacturing and operating vehicles. the company operates through automotive, sale financing, and mobility services segments. its automotive segment produces, sells, and distributes passenger cars and light commercial vehicles; and invests in automotive-sector associates and joint ventures primarily in nissan. the company's sale financing segment offers sale financing, leasing, maintenance, and services contract under the mobilize financial services brand. its mobility services segment provides mobility and energy solutions for electric vehicle users under the mobilize brand. in addition, it is also involved in the design, manufacture, and sale of passenger cars and light commercial vehicles and innovative services under the renault, dacia, alpine, and mobilize brands. further, the company offers used vehicles and spare parts; and engages in business to business powertrain activities, including exchange of powertrain parts and related engineering activities. renault sa was founded in 1898 and is based in boulogne-billancourt, france.

earnings per share

as for profitability, renault has a trailing twelve months eps of €6.07.

pe ratio

renault has a trailing twelve months price to earnings ratio of 5.83. meaning, the purchaser of the share is investing €5.83 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.64%.

moving average

renault's worth is higher than its 50-day moving average of €33.93 and above its 200-day moving average of €34.72.

more news about renault.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com